The FDA has announced the availability of a draft guidance for industry entitled “Labeling for Biosimilar and Interchangeable Biosimilar Products.” The guidance is intended to help applicants develop draft labeling for proposed biosimilar and interchangeable biosimilar products for submission in an application under section 351(k) of the Public Health Service Act (PHS Act) (42 U.S.C. 262(k)) (351(k) application).
In the new guidance, the FDA recommends that biosimilar and interchangeable biosimilar product labeling incorporate relevant data and information from the reference product labeling, with appropriate modifications. The relevant data and information from the reference product labeling that should be incorporated into the biosimilar and interchangeable biosimilar product labeling will depend on whether the applicant is seeking licensure for all conditions of use or fewer than all conditions of use for which the reference product has been previously licensed.




















